The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

PRISM Vision Group

Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader

Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)

Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)

Brigit

Advised Upbound Group, a technology and data-driven leader in accessible and inclusive financial products that address the evolving needs and aspirations of underserved consumers, on its acquisition of Brigit, a leading financial health technology company

Centogene GmbH

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases

Blue Owl Technology Finance Corp. II (“OTF II”)

Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF

Golub Capital LLC

Advising Mizuho Bank, Ltd., the banking arm of Mizuho Financial Group, Inc., on its purchase of a passive, non-voting minority stake in Golub Capital’s management companies

U.S. Operations of NextStream

Advised RadiusDC, a national owner and operator of highly-connected, urban-located data centers, on the acquistion of a series of entities comprising the U.S. operations of NextStream, a data center operator in Latin America owned by Actis

Medical Review Institute of America

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

U.S. Acute Care Solutions

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

Farmalider Group

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

Interest in Joint Venture with CarepathRx Health System Solutions

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

Clinigen Ltd’s Lamda Laboratories

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Gaming Services Division of Global Payments

Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm

Clinigen Ltd’s Proleukin

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

Kyowa Kirin International’s established medicines business

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company

GI Alliance

Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital

Theramex

Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners

Acacia Pharma Group plc

Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise

Alteon Health

Advised Alteon Health, a portfolio company of New Mountain Capital and national physician-led provider of emergency medicine, hospitalist medicine and post-acute care services, on its sale to U.S. Acute Care Solutions

Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products

Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS

GrowFlow Corp.

Advising Dama Financial, the nation’s largest provider of access to banking and payment solutions for the cannabis industry, on its acquisition of GrowFlow Corp, a leading business management and compliance software platform for cannabis retailers, cultivators, processors, and distributors

Procaps Group

Advised Procaps Group, a leading integrated international healthcare and pharmaceutical company, on its successful business combination with Union Acquisition Corp II (NASDAQ: LATN), a LatAm-focused special purpose acquisition company. Procaps Group now trades on the Nasdaq Global Market under the ticker symbol "PROC"

Faes Farma, flagship product Bilastine

Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America